Choose injectable BPC-157 if: Your target is a tendon, ligament, joint, or muscle injury You need systemic anti-inflammatory or tissue repair effects Speed and reliability of delivery matter You are working within a structured peptide therapy protocol with a licensed provider Choose oral BPC-157 if: Your primary concern is gut health leaky gut, IBD, IBS, gastric ulcers You want high local GI concentrations, not systemic distribution You prefer non-invasive administration for long-term or maintenance use You are combining BPC-157 with another systemic peptide therapy Consider nasal delivery only if: Neurological applications are the clinical focus A licensed provider explicitly recommends it based on your presentation Injection is contraindicated and oral delivery is insufficient Do not choose a delivery method based on convenience alone
For a more detailed discussion of our CY 2026 payment policy for skin substitutes, please see section V
There is no controlled human safety or efficacy data for the combination
It is also suggested benefits in joint health, including the treatment of muscle and ligament injuries
Certificate of Analysis Each batch is tested by an independent third-party laboratory for: Peptide identity verification Purity analysis via HPLC (99%) Microbial contaminant screening Heavy metal analysis Residual solvent testing Description DSIP is a nonapeptide first isolated from cerebral venous blood, supplied as a lyophilized 5mg vial for research use
Research suggests that GHK-Cu may suppress the production of inflammatory cytokines and modulate immune signaling pathways
